二甲双胍联合雌激素治疗青春期多囊卵巢综合征患者的效果

Effects of Metformin combined with Estrogen in treatment of adolescent polycystic ovary syndrome

目的:观察二甲双胍联合雌激素治疗青春期多囊卵巢综合征患者的效果。方法:选取2019年1月至2020年1月该院收治的80例青春期多囊卵巢综合征患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各40例。对照组采用雌激素治疗,观察组在对照组基础上联合二甲双胍治疗,比较两组临床疗效,治疗前后性激素指标[睾酮(T)、黄体生成素(LH)、卵泡刺激素(FSH)]水平,血糖指标[空腹胰岛素(FINS)、空腹血糖(FPG)、胰岛素抵抗指数(HOMA-IR)]水平及不良反应发生率。结果:观察组治疗总有效率为97.50%,高于对照组的75.00%,差异有统计学意义(P<0.05);治疗后,观察组T、LH、FSH水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组FINS、FPG、HOMA-IR水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:二甲双胍联合雌激素治疗青春期多囊卵巢综合征患者,可提高临床疗效,降低性激素指标和血糖指标水平,其效果优于单纯雌激素治疗。

Objective: To observe effects of Metformin combined with Estrogen in treatment of adolescent polycystic ovary syndrome.Methods: 80 adolescent patients with polycystic ovary syndrome admitted to our hospital from January 2019 to January 2020 were selected for prospective study and were divided into control group and observation group according to the random number table method, 40 cases in each group. The control group was treated with Estrogen, while the observation group was treated with Metformin on the basis of that of the control group. The clinical efficacy, the levels of sex hormone indexes [testosterone(T), luteinizing hormone(LH), and follicle-stimulating hormone(FSH)] before and after the treatment, the blood glucose indexes [fasting insulin(FINS), fasting blood glucose(FPG), homeostasis model assessment of insulin resistance(HOMA-IR)] levels and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the observation group was 97.50%, which was higher than 75.00% in the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of T, LH and FSH in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the levels of FINS, FPG and HOMA-IR in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Metformin combined with Estrogen in the treatment of the adolescent polycystic ovary patients can improve the clinical efficacy and reduce the levels of sex hormones, blood lipids and insulin. Moreover, it is superior to single Estrogen therapy alone.